Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

BioCardia outlines imminent CardiAMP FDA submission and targets regulatory catalysts as trial data signals clinical benefit [Seeking Alpha]

BioCardia, Inc. (BCDA) 
Company Research Source: Seeking Alpha
Peter Altman, CEO, highlighted that BioCardia now has complete and final data from three clinical trials of CardiAMP cell therapy, with the latest Phase III results presented as a late-breaking clinical trial. He emphasized, "The key Fresh Stock Ideas, Every Day Show less Read more
Impact Snapshot
Event Time:
BCDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for BCDA alerts
Opt-in for
BCDA alerts

from News Quantified
Opt-in for
BCDA alerts

from News Quantified